 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX  Get Free Report) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 20,300 shares, a drop of...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

LADENBURG THALM/SH SH lowered shares of Salarius Pharmaceuticals (NASDAQ:SLRX  Free Report) from a buy rating to a neutral rating in a report issued on Friday, FlyOnTheWall reports. Salarius Pharmaceuticals Stock Performance NASDAQ:SLRX opened at $0.65 on Friday. Salarius Pharmaceuticals has ...

Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded to "Neutral" at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH cut shares of Salarius Pharmaceuticals (NASDAQ:SLRX  Free Report) from a buy rating to a neutral rating in a research note released on Friday, FlyOnTheWall reports. Salarius Pharmaceuticals Trading Down 5.9 % Shares of SLRX stock opened at $0.65 on Friday. The business&#...

Salarius Pharmaceuticals (NASDAQ:SLRX) Lowered to "Neutral" at LADENBURG THALM/SH SH

Salarius Pharmaceuticals GAAP EPS of -$1.43

FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE...

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic ...

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

The trial will assess the safety and preliminary efficacy of Salarius novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be ...

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals (NASDAQ:SLRX  Get Rating) and Orgenesis (NASDAQ:ORGS  Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, ...

Salarius Pharmaceuticals (NASDAQ:SLRX) & Orgenesis (NASDAQ:ORGS) Financial Analysis

New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomideHOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and ...

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX  Get Rating)  Research analysts at Diamond Equity raised their Q2 2023 EPS estimates for Salarius Pharmaceuticals in a note issued to investors on Monday, May 15th. Diamond Equity analyst H. Diamond now forecasts that the company will post ...

Diamond Equity Analysts Lift Earnings Estimates for Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX)

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Watchers	12,369
52-Wk Low	$0.605
52-Wk High	$6.25

Market Cap	$2.4M
Volume (M)	3,957.00
52-Wk High	$6.25
52-Wk Low	$0.605

Current Price	$0.70
Prev Close	$0.6579
Open	$0.6776
Dividend Yield	0.00%
50-Day Moving Average	$0.8298
Beta	1.12
Avg. Volume	45,177.57
PE Ratio	-0.05

52-Week High	$6.25
52-Week Low	$0.605
Market Capitalization	$2.4M
EPS	-$12.90
Price to Book	0.26
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.35

SLRX Salarius Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals